Webinar on the Stage 1 Irritable Bowel Syndrome
Sydney, Oct 18, 2023 AEST (ABN Newswire) - Anatara Lifesciences (
ASX:ANR) is pleased to invite shareholders, investors and interested parties to an online Webinar on the Company's Stage 1 Irritable Bowel Syndrome (IBS) clinical trial results, hosted by Chair, Dr. David Brookes.
The webinar will be held on Thursday 19th October 2023 at 11:00am AEDT / 10:30am ACDT / 8:00am AWST
For the Q&A session, investors are invited to send questions for the webinar prior to 9:00am AEDT Thursday 19th October 2023 to: dirk@candouradvisory.com.au
Register for the webinar at the link below:
https://www.abnnewswire.net/lnk/LZPI0VFS
After registering, you will receive a confirmation email containing information about joining the webinar. A recording will be available at the above link shortly after the conclusion of the live session.
About Anatara Lifesciences Limited
Anatara Lifesciences Limited (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing productsfor human and animal health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.
| ||
|
